The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
Big opportunities for small molecules in immuno-oncology
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
The Chemokine Superfamily Revisited
Zlotnik, A., & Yoshie, O. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.008 · Cited by 1,235
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,179
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6752 · Cited by 1,047
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792
PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Rodriguez, P. C., Ernstoff, M. S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R., & Ochoa, A. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1921 · Cited by 773
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767
Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., & Borrello, I. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061104 · Cited by 766
CONTRIBUTION TO THE KNOWLEDGE OF SARCOMA
COLEY, W. B. (1891) · Annals of Surgery · doi:10.1097/00000658-189112000-00015 · Cited by 715
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Ribas, A., Hodi, F. S., Callahan, M., Konto, C., & Wolchok, J. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 714
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N. A., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15337 · Cited by 679
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215337 · Cited by 660
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., De Palma, A., Mauri, P., Monegal, A., Rescigno, M., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101956 · Cited by 650
Sanford, D. E., Belt, B. A., Panni, R. Z., Mayer, A., Deshpande, A. D., Carpenter, D., Mitchem, J. B., Plambeck-Suess, S. M., Worley, L. A., Goetz, B. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0525 · Cited by 613
Wang, C., Thudium, K. B., Han, M., Wang, X.-T., Huang, H., Feingersh, D., Garcia, C., Wu, Y., Kuhne, M., Srinivasan, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0040 · Cited by 601
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 572
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 572
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Ali, K., Soond, D. R., Piñeiro, R., Hagemann, T., Pearce, W., Lim, E. L., Bouabe, H., Scudamore, C. L., Hancox, T., Maecker, H., et al. (2014) · Nature · doi:10.1038/nature13444 · Cited by 529
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 521
Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P., & Owens, M. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.066 · Cited by 505
Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P., & Kalinski, P. (2011) · Blood · doi:10.1182/blood-2011-07-365825 · Cited by 497
Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477
Liu, L., Mayes, P. A., Eastman, S., Shi, H., Yadavilli, S., Zhang, T., Yang, J., Seestaller-Wehr, L., Zhang, S.-Y., Hopson, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2339 · Cited by 446
Self-citation(1997) · PubMed · Cited by 433
Macrophage Responses to Hypoxia
Lewis, C., & Murdoch, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62038-x · Cited by 413
Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., & Sitkovsky, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398
Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 390
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 386
Schmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378
Adenosine promotes alternative macrophage activation via A2A and A2B receptors
Csóka, B., Selmeczy, Z., Koscsó, B., Németh, Z. H., Pacher, P., Murray, P. J., Kepka‐Lenhart, D., Jr., S. M. M., Gause, W. C., Leibovich, S. J., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-190934 · Cited by 376
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 365
‘Cancer associated fibroblasts’ – more than meets the eye
Madar, S., Goldstein, I., & Rotter, V. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.004 · Cited by 362
Expression of P2X7 Receptor Increases In Vivo Tumor Growth
Adinolfi, E., Raffaghello, L., Giuliani, A. L., Cavazzini, L., Capece, M., Chiozzi, P., Bianchi, G., Kroemer, G., Pistoia, V., & Di Virgilio, F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1947 · Cited by 347
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 345
TLR agonists: our best frenemy in cancer immunotherapy
Kaczanowska, S., Joseph, A. M., & Davila, E. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012501 · Cited by 339
Chalmin, F., Mignot, G., Bruchard, M., Chevriaux, A., Végran, F., Hichami, A., Ladoire, S., Derangère, V., Vincent, J., Masson, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.019 · Cited by 338
Frey, D. M., Droeser, R. A., Viehl, C. T., Zlobec, I., Lugli, A., Zingg, U., Oertli, D., Kettelhack, C., Terracciano, L., & Tornillo, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24989 · Cited by 333
The Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 307
Khalili, J. S., Liu, S., Rodríguez-Cruz, T. G., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z. A., Frederick, D. T., Li, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1632 · Cited by 301
Kaidi, A., Qualtrough, D., Williams, A. C., & Paraskeva, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0425 · Cited by 300
Jie, H.-B., Gildener-Leapman, N., Li, J., Srivastava, R. M., Gibson, S. P., Whiteside, T. L., & Ferris, R. L. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.645 · Cited by 286
Schenk, U., Frascoli, M., Proietti, M., Geffers, R., Traggiai, E., Buer, J., Ricordi, C., Westendorf, A. M., & Grassi, F. (2011) · Science Signaling · doi:10.1126/scisignal.2001270 · Cited by 286
Induction of Heart Valve Lesions by Small-Molecule ALK5 Inhibitors
Anderton, M. J., Mellor, H. R., Bell, A., Sadler, C., Pass, M., Powell, S., Steele, S. J., Roberts, R. R. A., & Heier, A. (2011) · Toxicologic Pathology · doi:10.1177/0192623311416259 · Cited by 284
De Santo, C., Serafini, P., Marigo, I., Dolcetti, L., Bolla, M., Del Soldato, P., Melani, C., Guiducci, C., Colombo, M. P., Iezzi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409783102 · Cited by 284
Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Müller, C. E., Murakami, T., & Robson, S. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.007 · Cited by 279
Schuler, P. J., Saze, Z., Hong, C.-S., Muller, L., Gillespie, D. G., Cheng, D., Harasymczuk, M., Mandapathil, M., Lang, S., Jackson, E. K., et al. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12354 · Cited by 277
Mao, Y., Sarhan, D., Steven, A., Seliger, B., Kiessling, R., & Lundqvist, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0635 · Cited by 274
Small Molecule Inhibitors of CXCR4
Debnath, B., Xu, S., Grande, F., Garofalo, A., & Neamati, N. (2013) · Theranostics · doi:10.7150/thno.5376 · Cited by 273
Franciszkiewicz, K., Boissonnas, A., Boutet, M., Combadière, C., & Mami-Chouaib, F. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2027 · Cited by 272
North, R. A., & Jarvis, M. F. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.083758 · Cited by 270
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors
Muller, A. J., & Scherle, P. A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1929 · Cited by 262
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., & Zhang, B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45559 · Cited by 262
Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
Ryzhov, S., Novitskiy, S. V., Goldstein, A. E., Biktasova, A., Blackburn, M. R., Biaggioni, I., Dikov, M. M., & Feoktistov, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101225 · Cited by 261
Weed, D. T., Vella, J. L., Reis, I. M., De la fuente, A. C., Gomez, C., Sargi, Z., Nazarian, R., Califano, J., Borrello, I., & Serafini, P. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1711 · Cited by 261
Mahic, M., Yaqub, S., Johansson, C. C., Taskén, K., & Aandahl, E. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.246 · Cited by 248
Natural and Induced T Regulatory Cells in Cancer
Adeegbe, D. O., & Nishikawa, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00190 · Cited by 248
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Hoos, A., Ibrahim, R., Korman, A., Abdallah, K., Berman, D., Shahabi, V., Chin, K., Canetta, R., & Humphrey, R. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.015 · Cited by 242
Self-citationRodon, J., Carducci, M. A., Sepulveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1380 · Cited by 235
Yue, E. W., Douty, B., Wayland, B., Bower, M., Liu, X., Leffet, L., Wang, Q., Bowman, K. J., Hansbury, M. J., Liu, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900518f · Cited by 219
Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer
Ogino, S., Kirkner, G. J., Nosho, K., Irahara, N., Kure, S., Shima, K., Hazra, A., Chan, A. T., Dehari, R., Giovannucci, E. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1841 · Cited by 209
Specificity of the ecto‐ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases
Lévesque, S. A., Lavoie, É. G., Lecka, J., Bigonnesse, F., & Sévigny, J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707361 · Cited by 209
Fang, H., Ang, B., Xu, X., Huang, X., Wu, Y., Sun, Y., Wang, W., Li, N., Cao, X., & Wan, T. (2014) · Cellular & Molecular Immunology · doi:10.1038/cmi.2013.59 · Cited by 207
Knapp, K., Zebisch, M., Pippel, J., El-Tayeb, A., Müller, C. E., & Sträter, N. (2012) · Structure · doi:10.1016/j.str.2012.10.001 · Cited by 207
MSP–RON signalling in cancer: pathogenesis and therapeutic potential
Yao, H.-P., Zhou, Y.-Q., Zhang, R., & Wang, M.-H. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3545 · Cited by 204
ENTPD1/CD39 is a promising therapeutic target in oncology
Bastid, J., Cottalorda-Regairaz, A., Alberici, G., Bonnefoy, N., Eliaou, J.-F., & Bensussan, A. (2013) · Oncogene · doi:10.1038/onc.2012.269 · Cited by 202
Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
Cekic, C., Sag, D., Li, Y., Theodorescu, D., Strieter, R. M., & Linden, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101845 · Cited by 201
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response
Sitkovsky, M. V. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.12.002 · Cited by 193
Nakanishi, Y., Nakatsuji, M., Seno, H., Ishizu, S., Akitake-Kawano, R., Kanda, K., Ueo, T., Komekado, H., Kawada, M., Minami, M., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr128 · Cited by 190
STAT inhibitors for cancer therapy
Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-90 · Cited by 187
Pembrolizumab: First Global Approval
Poole, R. M. (2014) · Drugs · doi:10.1007/s40265-014-0314-5 · Cited by 184
Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma
Califano, J. A., Khan, Z., Noonan, K. A., Rudraraju, L., Zhang, Z., Wang, H., Goodman, S., Gourin, C. G., Ha, P. K., Fakhry, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1716 · Cited by 184
Aswad, F., Kawamura, H., & Dennert, G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3075 · Cited by 183
Peri, F., & Calabrese, V. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401006s · Cited by 181
Yan, M., Jene, N., Byrne, D., Millar, E. K., O'Toole, S. A., McNeil, C. M., Bates, G. J., Harris, A. L., Banham, A. H., Sutherland, R. L., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2869 · Cited by 180
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation
Stewart, C. A., Metheny, H., Iida, N., Smith, L., Hanson, M., Steinhagen, F., Leighty, R. M., Roers, A., Karp, C. L., Müller, W., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65180 · Cited by 173
Dudek, A. Z., Yunis, C., Harrison, L. I., Kumar, S., Hawkinson, R., Cooley, S., Vasilakos, J. P., Gorski, K. S., & Miller, J. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1443 · Cited by 173
Holt, D., Ma, X., Kundu, N., & Fulton, A. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1064-9 · Cited by 171
Jin, C. H., Krishnaiah, M., Sreenu, D., Subrahmanyam, V. B., Rao, K. S., Lee, H. J., Park, S.-J., Park, H.-J., Lee, K., Sheen, Y. Y., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500115w · Cited by 162
Mandapathil, M., Szczepanski, M. J., Szajnik, M., Ren, J., Jackson, E. K., Johnson, J. T., Gorelik, E., Lang, S., & Whiteside, T. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127100 · Cited by 162
af Forselles, K., Root, J., Clarke, T., Davey, D., Aughton, K., Dack, K., & Pullen, N. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01495.x · Cited by 161
Iannone, R., Miele, L., Maiolino, P., Pinto, A., & Morello, S. (2013) · Neoplasia · doi:10.1593/neo.131748 · Cited by 156
Sikalidis, A. K. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-014-9860-0 · Cited by 156
Improving cancer immunotherapy by targeting tumor-induced immune suppression
Stewart, T. J., & Smyth, M. J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9280-5 · Cited by 156
P2X7: a growth-promoting receptor—implications for cancer
Virgilio, F. D., Ferrari, D., & Adinolfi, E. (2009) · Purinergic Signalling · doi:10.1007/s11302-009-9145-3 · Cited by 143
Serra, S., Horenstein, A. L., Vaisitti, T., Brusa, D., Rossi, D., Laurenti, L., D'Arena, G. F., Coscia, M., Tripodo, C., Inghirami, G., et al. (2011) · Blood · doi:10.1182/blood-2011-08-374728 · Cited by 142
P2X7 Integrates PI3K/AKT and AMPK-PRAS40-mTOR Signaling Pathways to Mediate Tumor Cell Death
Shu, B., Sun, X., Bai, A., Zhang, C., Li, L., Enjyoji, K., JUNGER, W. G., Robson, S. C., & Wu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060184 · Cited by 138
Weitzenfeld, P., & Ben‐Baruch, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.006 · Cited by 134
TGF-β and kynurenines as the key to infectious tolerance
Belladonna, M. L., Orabona, C., Grohmann, U., & Puccetti, P. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.006 · Cited by 134
ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment
Bianchi, G., Vuerich, M., Pellegatti, P., Marimpietri, D., Emionite, L., Marigo, I., Bronte, V., Virgilio, F. D., Pistoia, V., & Raffaghello, L. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.109 · Cited by 133
The Role of Anti-Inflammatory Drugs in Colorectal Cancer
Wang, D., & DuBois, R. N. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-112211-154330 · Cited by 127
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells
Schilling, B., Sucker, A., Griewank, K., Zhao, F., Weide, B., Görgens, A., Giebel, B., Schadendorf, D., & Paschen, A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28168 · Cited by 124
Yang, M., Ma, C., Liu, S., Shao, Q., Gao, W., Song, B., Sun, J., Xie, Q., Zhang, Y., Feng, A., et al. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2009.77 · Cited by 115
al‐Rashida, M., & Iqbal, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.21302 · Cited by 105
Xu, S., Shao, Q., Sun, J., Yang, N., Xie, Q., Wang, D., Huang, Q., Huang, B., Wang, X., Li, X., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not067 · Cited by 103
Ma, X., Holt, D. M., Kundu, N., Reader, J. C., Goloubeva, O. G., Take, Y., & Fulton, A. M. (2013) · OncoImmunology · doi:10.4161/onci.22647 · Cited by 99
Serafini, P. (2013) · Immunologic Research · doi:10.1007/s12026-013-8455-2 · Cited by 97
Induced regulatory T cells in inhibitory microenvironments created by cancer
Whiteside, T. L. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.927432 · Cited by 97
Zandt, M. C. V., Whitehouse, D. L., Gołȩbiowski, A., Ji, M. K., Zhang, M., Beckett, R. P., Jagdmann, G. E., Ryder, T. R., Sheeler, R., Andreoli, M., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400014c · Cited by 94
de Boniface, J., Mao, Y., Schmidt‐Mende, J., Kiessling, R. W., & Poschke, I. C. (2012) · OncoImmunology · doi:10.4161/onci.21678 · Cited by 91
Distinct Roles of Adenylyl Cyclase VII in Regulating the Immune Responses in Mice
Duan, B., Davis, R., Sadat, E. L., Collins, J. N. R., Sternweis, P. C., Yuan, D., & Jiang, L. I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903474 · Cited by 88
Peled, A., Abraham, M., Avivi, I. M., Rowe, J. M., Beider, K., Wald, H., Tiomkin, L., Ribakovsky, L., Riback, Y., Ramati, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1302 · Cited by 88
Hilchey, S. P., Kobie, J. J., Cochran, M. R., Secor‐Socha, S., Wang, J.-C. E., Hyrien, O., Burack, R., Mosmann, T. R., Quataert, S. A., & Bernstein, S. H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900475 · Cited by 87
Inhibition of CD73 Improves B Cell-Mediated Anti-Tumor Immunity in a Mouse Model of Melanoma
Forte, G., Sorrentino, R., Montinaro, A., Luciano, A., Adcock, I. M., Maiolino, P., Arra, C., Cicala, C., Pinto, A., & Morello, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200744 · Cited by 86
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
Michaud, M., Sukkurwala, A. Q., Martins, I., Shen, S., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19070 · Cited by 74
Yoon, J., Jung, S. M., Park, S. H., Kato, M., Yamashita, T., Lee, I., Sudo, K., Nakae, S., Han, J. S., Kim, O., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302524 · Cited by 73
Whiteside, T. L., & Jackson, E. K. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00212 · Cited by 67
Northfelt, D., Ramanathan, R. K., Cohen, P. A., Hoff, D. D. V., Weiss, G. J., Dietsch, G. N., Manjarrez, K. L., Randall, T. D., & Hershberg, R. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0392 · Cited by 66
Regulation of cAMP Responses by the G12/13 Pathway Converges on Adenylyl Cyclase VII
Jiang, L. I., Collins, J. N. R., Davis, R., Fraser, I. D. C., & Sternweis, P. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803281200 · Cited by 66
Sullivan, R. J., LoRusso, P. M., & Flaherty, K. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2151 · Cited by 64
A methodological framework to enhance the clinical success of cancer immunotherapy
Hoos, A., Britten, C. M., Huber, C., & O’Donnell-Tormey, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.2000 · Cited by 60
Self-citationDirecting the Immune System with Chemical Compounds
Mancini, R. J., Stutts, L., Ryu, K. A., Tom, J. K., & Esser-Kahn, A. P. (2014) · ACS Chemical Biology · doi:10.1021/cb500079s · Cited by 57
Yoon, J., Jung, S. M., Park, S. H., Kato, M., Yamashita, T., Lee, I., Sudo, K., Nakae, S., Han, J. S., Kim, O., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201470040 · Cited by 57
Idelalisib—targeting PI3Kδ in patients with B-cell malignancies
Burger, J. A., & Okkenhaug, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.42 · Cited by 56
Sitkovsky, M. V., & Ohta, A. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1001-9 · Cited by 51
A Beginner’s Guide To Chemokines
Vinader, V. M., & Afarinkia, K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.49 · Cited by 41
The Emerging Role of CXC Chemokines And Their Receptors in Cancer
Vinader, V. M., & Afarinkia, K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.48 · Cited by 38
Targeting regulatory T cells in tumor immunotherapy
Smyth, M. J., Ngiow, S. F., & Teng, M. W. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.33 · Cited by 32
Chemokine–Chemokine Receptors in Cancer Immunotherapy
Stewart, T. J., & Smyth, M. J. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.109 · Cited by 32
Gerard, C. M., Baudson, N., Ory, T., & Louahed, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094883 · Cited by 32
RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses
Eyob, H., Ekiz, H. A., & Welm, A. L. (2013) · OncoImmunology · doi:10.4161/onci.25670 · Cited by 23
Hagos, G. K., Abdul‐Hay, S. O., Sohn, J., Edirisinghe, P. D., Chandrasena, R. E. P., Wang, Z., Li, Q., & Thatcher, G. R. J. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.046664 · Cited by 16
A phase I study of HYB2055 in patients (pts) with advanced solid malignancies
Hwang, J. J., Park, S., Amin, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3111 · Cited by 7
Cited by
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Metabolic Instruction of Immunity
Buck, M. D., Sowell, R. T., Kaech, S. M., & Pearce, E. L. (2017) · Cell · doi:10.1016/j.cell.2017.04.004 · Cited by 1,214
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
“The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
BackgroundInfluentialTargeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Self-citation
Metadata
- Authors
- Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-07-31
- Volume
- 14
- Issue
- 9
- Pages
- 603-622
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1800636867
- Cited by
- 471
- References
- 155
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.